Related Experiment Video
Updated: Jan 14, 2026
18:48
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
14.8K
Effect of Statin Intensity on Tolerability, Lipid Levels, and Cardiac Function After Transplantation
Dou Huang1, Eric Hirsch2, Kyung Taek Oh3
1From the Division of Cardiology, Department of Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|October 27, 2025
Summary
Intensified statin therapy is well-tolerated in heart transplant recipients, improving LDL cholesterol control and preserving cardiac function without increased side effects.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Statins are crucial for reducing coronary vasculopathy and mortality post-heart transplantation (HT).
- The safety and efficacy of intensified statin regimens in preserving cardiac function after HT require further investigation.
Purpose of the Study:
- To evaluate the tolerability and impact of intensified statin therapy on cardiac function and lipid levels in heart transplant recipients.
Main Methods:
- A retrospective cohort study analyzed 277 adult single-organ HT recipients (2012-2021).
- Patients were categorized into standard-intensity and intensified-statin groups.
- Outcomes included statin intolerability, low-density lipoprotein (LDL) levels, and left ventricular global longitudinal strain.
Main Results:
- Statin intolerability rates were similar between standard (7%) and intensified (3%) groups (p=0.56).
- Intensified statin use maintained stable LDL levels at 1 year post-HT, unlike standard statin use which showed an increase (p=0.01).
- Patients on intensified statin exhibited better preservation of myocardial function, indicated by higher left ventricular global longitudinal strain at 1-3 years post-HT (p=0.03).
Conclusions:
- Intensified statin therapy is safe and well-tolerated in heart transplant recipients.
- Higher-intensity statins offer superior LDL cholesterol control and are associated with improved myocardial function preservation after HT.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
01:28Kidney Transplant I: Introduction
339
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
339
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
210
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
210